Thomas Ferrari, MD
Internal Medicine · Swainsboro, GANPI 1346249109
Payments from drug & device makers
Across 139 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$523
- Lilly USA, LLC$198
- Sanofi-aventis U.S. LLC$175
- Vanda Pharmaceuticals Inc.$156
- AstraZeneca$155
- Novo Nordisk$135
- plus $950 from 25 others
What the payments were for
- Food & beverage$2,24898%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $523 |
| Lilly USA, LLC | 11 | $198 |
| Sanofi-aventis U.S. LLC | 10 | $175 |
| Vanda Pharmaceuticals Inc. | 7 | $156 |
| AstraZeneca | 10 | $155 |
| Novo Nordisk | 9 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $130 |
| GSK | 7 | $115 |
| Novartis | 6 | $110 |
| Pfizer | 4 | $62 |
| Boehringer Ingelheim | 3 | $48 |
| Exact Sciences | 3 | $47 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Johnson & Johnson | 3 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Amgen | 2 | $29 |
| Biogen | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Ardelyx, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$2,293 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 161 | $192,217 |
| OzempicSemaglutide | 162 | $186,225 |
| RybelsusSemaglutide | 61 | $116,529 |
| EliquisApixaban | 85 | $91,206 |
| TrulicityDulaglutide | 56 | $78,069 |
| FarxigaDapagliflozin Propanediol | 81 | $74,937 |
| RexultiBrexpiprazole | 36 | $66,291 |
| JardianceEmpagliflozin | 63 | $65,798 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $65,750 |
| LinzessLinaclotide | 39 | $43,441 |
| CreonLipase/Protease/Amylase | 12 | $31,668 |
| VascepaIcosapent Ethyl | 56 | $25,792 |
| MyrbetriqMirabegron | 32 | $25,072 |
| JanuviaSitagliptin Phosphate | 35 | $22,486 |
| VraylarCariprazine Hcl | 15 | $21,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $135 | $302,755223 claims |
| Lilly USA, LLCMounjaro, Trulicity | $198 | $270,286217 claims |
| AbbVieLinzess, Creon, Vraylar, Namzaric | $523 | $112,95794 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $155 | $96,079116 claims |
| PfizerEliquis | $62 | $91,20685 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $48 | $81,86279 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $13 | $66,29136 claims |
| GSKTrelegy Ellipta | $115 | $65,75068 claims |
| MerckJanuvia | $12 | $22,48635 claims |
| Johnson & JohnsonXarelto | $39 | $14,75322 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $130 | $10,80020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Swainsboro
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.